Health

STAT+: Why the latest heart drug failures should make us all more skeptical of AI hype

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 08/11/2026, 18:51:24 UTC.

Briefings

Two recent heart drug trials presented at the American Heart Association failed to show benefits despite genetic improvements, challenging AI hype claims. Novartis's pelacarsen and Novo Nordisk's IL-6 inhibitor showed no impact on heart attack or stroke rates. This evidence suggests skepticism toward technology promises is warranted.

Key points

• Novartis's pelacarsen drug showed no effect on heart attack or stroke rates despite lowering Lp(a) levels.
• A Novo Nordisk study targeting IL-6 also demonstrated no benefit for cardiovascular outcomes.

Context

Pharmaceutical researchers have repeatedly learned that technologies intended to speed new medicines often fail. Two studies presented at the American Heart Association's annual meeting illustrate this pattern.

Limitations

Evidence is limited to two studies presented at the American Heart Association's annual meeting in 2026. Results are preliminary and do not represent long-term clinical data.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 08/11/2026, 19:05:33 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeigkhkdr4mtubrn5vdn5cvn4mvg4oafhpn32mermt3jtpmriansxiu